- Abeona Therapeutics (NASDAQ:ABEO) is up 4% premarket on light volume on the heels of its announcement that the European Medicines Agency has designated gene therapy ABO-202 an Orphan Drug for the treatment of neuronal ceroid lipofuscinosis, known as Batten disease, a fatal inherited lysosomal storage disorder that primarily affects the nervous system in children.
- Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.
Abeona's ABO-202 an Orphan Drug in Europe for Batten disease; shares up 4% premarket
Recommended For You
About ABEO Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ABEO | - | - |
Abeona Therapeutics Inc. |